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Purpose/Objective: Intensity-modulated radiotherapy (IMRT) offers 
an avenue to limit side effects. This study attempted to define the 
percentage of patient with Primary Central Nervous System Lymphoma 
(PCNSL) located within the hippocampal region in order to explore the 
feasibility of avoiding the hippocampus during whole-brain 
radiotherapy to prevent radiation-induced neurocognitive decline. 
Materials and Methods: Patients (> 18 years, ECOG <4) with 
pathologically proven PCNSL and MRI image pre treatment were 
retrospectively reviewed. All patients had been treated with WBRT 
after high-dose of methotrexate (HD-MTX). T1-weighted, post-contrast 
axial MR image sets obtained prior to cranial irradiation were 
collected and imported on Varian Eclipse treatment planning system, 
version 8.9 (Varian Medical Systems). Coregistered CT-MRI axial image 
sets were used to contour the hippocampus as well as each PCNSL 
lesions. The resulting hippocampal regions were expanded to create 
three-dimensional envelopes surrounding the hippocampus at 5, 10, 
and 15 mm and the distance of brain lesions were recorded as <5 mm, 
5 to <10 mm, 10 to <15 mm, and >15 mm from the hippocampus. The 
minimum margin of 5 mm was taken account for systematic setup 
error and dose fall-off between whole brain clinical target volume and 
the hippocampus. 
Results: From 2006 to 2012, 22 patients were treated and 16 pts with 
30 lesions were eligible for this study. In five patients PCNSL lesions 
were in more than one lobe: parietal was the most involved one (37%), 
then deep brain structures and the temporal lobe in 16% respectively, 
the frontal in 14%, the occipital in 9%, and the brainstem in 8% of 
cases. Six out of sixteen patients (37%) had PCNSL within 5 mm of the 
hippocampus. Of the 30 identified PCNSL lesions, 57% (n = 17) were 
localized over 15 mm of hippocampal region. Within 5 mm of the 
hippocampus we observed 20% (n = 6) of brain lesions, two of them 
involved the hippocampus, while 10% (n = 3) and 13% (n=4) were 
within 10 and 15 mm respectively. 
Conclusions: Although the 80% of PCNSL lesions were diagnosed over 5 
mm from the hippocampus, it is not recommended an hippocampal 
sparing in all patients, but it has to be evaluated for each one. When 
the spatial distribution of PCNSL is far enough to allow the 
hippocampal sparing, it could be proposed an IMRT treatment plan. 
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Purpose/Objective: To construct a mathematical model of tumor 
progression incorporating the basic facts of low grade glioma (LGG) 
progression and response to therapy. 
Materials and Methods: We have adopted a continous model where 
C(x,t) is the tumor cell concentration as a function of time and spatial 
position x. D is the diffusion coefficient accounting for the average 
cellular motility measured in mm2/day to be assumed to be constant 
and spatially uniform. Theparameter r is the proliferation rate (1/day) 
giving an estimate of the typical cell doubling times. We have chosen 
a logistic type of proliferation. The response of the tumor to radiation 
has been captured with an equation for the evolution of the density of 
damaged cells after irradiation Cd(x,t). The parameter k is the 
average number of mitosis cycles that damaged cells are able to 
complete before dying. We will assume the fraction of tumor cells 
damaged by a radiation dose to be given by the classical linear-
quadratic model. Parameter estimation: For the cell diffusion 
coefficient we have taken values around D = 0.0075 mm2/day; for 
proliferation rate we have considered values ranging from r =0.001 
day-1 for very slowly growing LGGs to r =0.01 day-1. As to the 
radiobiological parameters, being gliomas very radioresistant tumors, 
we have taken values in the range SF1.8Gy ≈0.9. Finally, the average 
number of mitosis cycles completed before mitotic catastrophe occurs 
has been considered in the range k = 1-3. The simulated radiotherapy 
scheme was an standard fractionation of a total of 54 Gy in 30 
fractions of 1.8 Gy over a time range of 6 weeks. The model output 
was compared with the results of a recent retrospective quantitative 
study of LGG response to radiation by Pallud et al. (2012). 
Results: Tumor proliferation rates determines the response to 
radiotherapy. The lower the proliferationrate, the longer time to 
tumor progression and survival rates. The more proliferative tumors 
respond earlier to therapy but bear an adverse prognosis.The 
parameter k does not have a crucial role on the clinically relevant 
parameters. Cell motility does not affect too much the dynamics of 
the response to therapy, but has a relevant impact on the survival 
time. Defering radiotherapy or splitting doses does not affect survival 
time. This concept opens the door to novel treatment strategies 
where part of the radiation is given right after surgery and the 
remaining radiation could be given on progression, deferring the time 
of appearance of side effects. The response of the tumor to the first 
radiotherapy course will provide information regarding tumor 
proliferation rate and guide the clinician for additional treatments. 
Conclusions: The model provides an explanation to the observations 
of published retrospective studies and could be used to suggest novel 
radiation therapy strategies that might be clinically useful. 
   
EP-0996   
Simultaneous in field boost helical tomotherapy for patients with 1-
3 brain metastases. 
M. Galeandro1, F. Vigo1, A. Podgornii1, P. Ciammella1, D. Ramundo1, A. 
Botti2, C. Iotti1 
1Arcispedale S. Maria Nuova, Advanced Technology, Reggio Emilia, 
Italy  
2Arcispedale S. Maria Nuova, Medical Physic Department, Reggio 
Emilia, Italy  
 
Purpose/Objective: The objective of this study was to evaluate the 
overall survival (OS), intracranial control (ICC) and intralesional (ILC) 
after IGRT-IMRT with SIB. Inclusion criteria were: maximum 3 brain 
mts, ≤ 3 cm of diameter, good performance status (KPS≥ 70), no 
previous cranial RT and with systemic stable disease.  
Materials and Methods: Between May 2010 and November 2011, 21 
patients with 44 brain mts were treated with IGRT-IMRT with SIB at 
our Hospital. Primary cancers were NSCLC in the majority cases (n = 
11), breast cancer (n = 6), colon cancer (n = 1), melanoma (n = 2) and 
other sites (n = 1). 8 patients had a solitary brain lesion, while 18 
patients had 2 to 3 lesions. 
All patients were immobilized in the supine position in a tight 
thermoplastic stereotactic head mask. Helical computed tomography 
(CT) images of 3-mm thickness were obtained. Gross tumor volume 
(GTV) was defined by the tumor on CT scans registered with MRI. 
Planning target volume (PTV) was defined by adding a margin of 3 mm 
to the GTV. In association with WBRT, a SIB was administered to all 
brain lesions. A composite IMRT plan was generated for all patients 
consisting in WBRT (30 Gy/10 fx) with a SIB of 6 Gy in 10 fractions. 
Patients were treated in with Tomotherapy Hi-ART, with positioning 
determined by co-registration of the simulation kV CT scan with a 
MVCT scan acquired on the treatment unit. Patients underwent 
clinical follow-up examinations every 3 months so that we could 
evaluate their disease status, neurologic symptoms, and performance 
status. 
Results: At the time of the last follow-up that was conducted in May 
of 2012, 5 patients had survived, and 16 were deceased. The median 
follow-up time of alive patients was 14 months (6-17 months). The 
median survival time was 12 months. The overall survival rate at 6 and 
12-months was 94% and 30%, respectively. Two patients experienced 
intralesional progression of large lesions and five developed new brain 
metastases. Intracranial control was observed in 15 patients.  
No acute toxicity was observed. Late toxicity consisting of grade 2-3 
brain edema occurred in 5 patients, and it presented as uncontrollable 
headaches. Four out of 5 of these patients developed new brain mts. 
Only 1 patient died of brain edema. Of the 17 patients who died, 8 
died of extracranial disease progression, 6 died of intracranial disease 
progression and 1 each died of brain edema. The cause of death for 
the remaining 2 patients was unknown. The following factors were 
analyzed in order to determine whether they were related to the 
prognosis of survival and local tumor control: gender, age, number of 
brain metastases (1, > 2), status of primary tumor, status of 
extracranial mts, KPS, and RPA class. Controlled primary tumors and 
KPS scores of 80 or more were advantageous prognostic factors of 
survival. No factor was identified as a significant predictor of local 
tumor control.  
Conclusions: The delivery of 60 Gy in 10 fx using a SIB technique was 
achieved with no significant toxicity. Stable systemic disease and KPS 
scores > 80 were advantageous prognostic factors of survival. OS 
benefits need to be confirmed by large randomized studies.  
